Drug combinations in the treatment of refractory depression: a review.
The authors critically review several drug combinations that may be of promise in the management of depressions that do not respond to treatment with a single drug. These include the use of tricyclic antidepressants with monoamine oxidase inhibitors (MAOI's), L-triiodothyronine (T3), methylphenidate, lithium carbonate, L-tryptophan, reserpine, and neuroleptics; MAOI's with lithium and L-tryptophan; and L-tryptophan with allopurinol. The authors stress the need for further double-blind, controlled studies to evaluate the safety and efficacy of these combinations.
D000493:Allopurinol / Q000008:administration & dosage; D000928:Antidepressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage; D014150:Antipsychotic Agents / Q000008:administration & dosage; D003866:Depressive Disorder / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D008094:Lithium / Q000008:administration & dosage; D008774:Methylphenidate / Q000008:administration & dosage; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage; D012110:Reserpine / Q000008:administration & dosage; D014284:Triiodothyronine / Q000008:administration & dosage; D014364:Tryptophan / Q000008:administration & dosage
D000928:Antidepressive Agents; D000929:Antidepressive Agents, Tricyclic; D014150:Antipsychotic Agents; D008996:Monoamine Oxidase Inhibitors; D014284:Triiodothyronine; D008774:Methylphenidate; D000493:Allopurinol; D012110:Reserpine; D014364:Tryptophan; D008094:Lithium